
Danish pharmaceutical company Novo Nordisk signed a deal with South Africa's Aspen Pharmacare to produce human insulin for diabetes patients in Africa, where there is a dire need for the life-saving treatment.
The Africa Centers for Disease Control and Prevention welcomed the move Wednesday, saying it would “greatly impact the fight against diabetes” in Africa.